Gastric cancer prevention from the point of helicobacter

Kaynakça (5)

1. Stomach Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/ fact_sheets_cancer.aspx
2. Galiatsatos P, Wyse J, Szilagyi A. H. Pylori Biopsy Accuracy in Intestinal Metaplasia. Turk J Gastroenterol 2014; 25: 19-23. [CrossRef] 3. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975; 2: 58-60. [CrossRef] 4. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48: 3554-60
3. Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis 2012; 13: 2-9. [CrossRef] 6. Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol 2013; 27: 205-23. [CrossRef] 7. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-64. [CrossRef] 8. Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G, Dammacco F. H. pylori infection and gastric cancer: state of the art (review). Int J Oncol 2013; 42: 5-18
4. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans- ancient history, modern implications. J Clin Invest 2009; 119: 2475-87. [CrossRef] 10. IARC Working Group: Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1-241
5. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after H. pylori eradi- cation: a meta-analysis. Digestion 2011; 83: 253-60. [CrossRef] 12. Kodama M, Murakami K, Okimoto T, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicob acter pylori eradication. J Gastroenterol 2012; 47: 394-403. [CrossRef] 13. Malfertheiner P. Gastric atrophy reversible or irreversible after Helicobacter pylori eradication - An open question. Digestion 2011; 83: 250-2. [CrossRef] 14. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44: 74-94. [